News / Finance
WhisperfromWallStreet.com "Morning Wake Up Call - " - Haemonetics Corp.,HAE - Hemispherx Biopharma, Inc,HEB - Axsys Technologies, Inc.,AXYS
Haemonetics Corp. - Hemispherx Biopharma - Axsys Technologies
Haemonetics Corp.,HAE
Haemonetics receives favorable ruling in patent lawsuit against competitive technology (HAE) 54.67 -0.22 : Co announces that the U.S. District Court for the District of Massachusetts has made a ruling in the Company's lawsuit against Fenwal. In January 2009, a jury issued a verdict in favor of Haemonetics, finding that Fenwal's ALYX Component Collection System consumable infringes a U.S. Haemonetics patent. The jury awarded Haemonetics $15.7 million in damages for past infringement. On June 2, 2009, the Court further ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December 1, 2010 and must pay Haemonetics a 10% royalty on ALYX consumable net sales from January 30, 2009 until December 1, 2010 when the injunction takes effect. In addition, the court awarded pre-judgment interest at 5% on the unpaid damages awarded. These rulings may be appealed by Fenwal and/or Baxter.
Last Trade: 54.40
Day's Range: 54.23 - 54.95
52wk Range: 46.78 - 67.49
Volume: 310,480
---
If you are viewing this press release you are obviously interested in making money in the stock market. In today’s market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
Hemispherx Biopharma, Inc,HEB
Hemispherx Biopharma announces Japanese National Institute of Infectious Diseases scientists identify its drug technology as the "most promising mucosal adjuvant for influenza" (HEB) 2.68 +0.14 : Co announces that a new publication summarizes ongoing research in which researchers conclude that Poly I:PolyC12U (Ampligen, an experimental therapeutic, is the "most promising adjuvant candidate for mucosal vaccines." Ampligen was also "extremely important" in these studies, in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone." The conclusion of the JIID researchers is that a pandemic of new influenza virus seems possible, and because it will be difficult to know when a pandemic will occur (or which strain of virus will be the cause), it is in the global community's best interest to develop broadly effective and safe vaccines against influenza virus. Hence, in the need for development of a broadly effective vaccine, induction of mucosal immunity is an inevitable requirement, as mucosal secretory IgA plays an important role in cross protection.
Last Trade: 2.89
Day's Range: 2.64 - 2.95
52wk Range: 0.25 - 2.79
Volume: 6,309,062
---
Axsys Technologies, Inc.,AXYS
Axsys Technologies to be acquired by General Dynamics for $54 per share (AXYS) 50.00 : General Dynamics Advanced Information Systems, a business unit of General Dynamics (GD), has entered into a definitive agreement to acquire AXYS for $54 per share of Axsys Technologies' outstanding common stock. The cost of the transaction would be $643 mln. The proposed acquisition, which has been approved by the boards of directors of Axsys Technologies and General Dynamics, would be earnings-neutral in 2009 and accretive to General Dynamics' earnings thereafter.
Last Trade: 53.04
Day's Range: 52.75 - 53.75
52wk Range: 24.35 - 79.69
Volume: 1,321,418
----
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
